Lifecycle of a Medical Device

The regulatory lifecycle of a medical device in Canada spans from initial concept through to eventual market withdrawal. Health Canada's requirements apply at multiple stages.

Stage 1 — Concept and design

During the concept and early design phase, key regulatory activities include:

• Determining if the product is a medical device — see What is a Medical Device?
• Classifying the device — determine the applicable class (I–IV) under Schedule 2 of the MDR — see How Classification Works
• Understanding the regulatory pathway — Device Licence vs. MDEL-only
• Engaging Health Canada early — for novel or complex devices, a Pre-Submission Meeting helps clarify requirements before significant investment

Stage 2 — Development and testing

During product development:

• Design controls (documented in the QMS per ISO 13485) must be applied
• Safety and effectiveness testing against Schedule 1 requirements and applicable recognised standards must be conducted
• For Class III and IV devices, clinical evidence must be generated or gathered
• Risk management per ISO 14971 must be conducted and documented
• For devices used in clinical investigations, an Investigational Testing Authorization (ITA) may be required

Stage 3 — Pre-market authorisation

Before the device can be sold in Canada:

• Class I devices: importer/distributor must hold an MDEL — no Device Licence needed
• Class II–IV devices: manufacturer must obtain a Device Licence from Health Canada
• The Device Licence application must include safety and effectiveness evidence, labelling (bilingual), standards compliance, and QMS documentation

Stage 4 — Market entry

Once licensed:

• The device is listed in the Medical Devices Active Licence Listing (MDALL) database
• Importers and distributors must hold a current MDEL
• Bilingual labelling (English and French) must be in place before placing the device on the Canadian market

Stage 5 — Post-market (ongoing)

After market entry, ongoing obligations include:

• Mandatory problem reporting — reporting device-related incidents within defined timeframes
• Post-market surveillance — systematic monitoring of device performance — see PMS Requirements
• Recalls — removing or correcting devices when a safety issue arises — see When a Recall is Required
• Licence amendments — notifying Health Canada of changes that affect safety, effectiveness, or labelling
• MDEL maintenance — keeping establishment licence information current
• Annual charges — paying annual fees to maintain the Device Licence

Stage 6 — Product changes

Throughout the product lifecycle, changes to the device may require:

• A Device Licence amendment for changes that affect safety, effectiveness, or labelling
• Updating the risk management file
• Re-validation of affected design elements

Stage 7 — Market withdrawal

When a device is withdrawn from the Canadian market:

• The manufacturer may request cancellation of the Device Licence
• Health Canada publishes the cancellation in the MDALL database
• Post-market obligations (including responding to outstanding incidents and completing any ongoing recalls) continue until all distributed devices are accounted for
• Distribution records must be retained for at least 2 years of the device, or as otherwise specified by Health Canada. after the last distribution

Expand the post-market surveillance bullet point to: Post-market surveillance — systematic monitoring of device performance through complaint analysis, adverse event trends, and other surveillance mechanisms appropriate to the device class and risk profile. Class III and IV devices typically require more robust surveillance plans.